Aclaris Therapeutics, Inc. (ACRS)
| Market Cap | 621.50M +298.6% |
| Revenue (ttm) | 8.37M -52.9% |
| Net Income | -69.66M |
| EPS | -0.56 |
| Shares Out | 139.66M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,195,714 |
| Open | 4.350 |
| Previous Close | 4.400 |
| Day's Range | 4.340 - 4.510 |
| 52-Week Range | 1.220 - 5.150 |
| Beta | 0.78 |
| Analysts | Strong Buy |
| Price Target | 9.67 (+117.3%) |
| Earnings Date | May 7, 2026 |
About ACRS
Aclaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering and developing novel molecule product candidates for immuno-inflammatory diseases in the United States. The company product pipeline includes Bosakitug (ATI-045), an anti-thymic stromal lymphopoietin monoclonal antibody in Phase 2 trial to treat moderate to severe atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyps, and moderate to severe chronic obstructive pulmonary disease; ATI-2138, an potent and selective novel investigational... [Read more]
Financial Performance
In 2025, Aclaris Therapeutics's revenue was $7.83 million, a decrease of -58.19% compared to the previous year's $18.72 million. Losses were -$64.92 million, -50.84% less than in 2024.
Financial StatementsAnalyst Summary
According to 10 analysts, the average rating for ACRS stock is "Strong Buy." The 12-month stock price target is $9.67, which is an increase of 117.30% from the latest price.
News
Aclaris Therapeutics Transcript: Bank of America Global Healthcare Conference 2026
Innovative immunology pipeline targets dermatologic and respiratory diseases with both biologics and small molecules, including best-in-class anti-TSLP and ITK inhibitors. Multiple phase II and IND milestones are expected by year-end, supported by a strong cash position.
Aclaris Therapeutics Slides: FY 2026
Aclaris Therapeutics has posted slides in relation to its FY 2026 quarterly earnings report, which was published on May 14, 2026.
Aclaris Therapeutics to Participate in the 2026 Bank of America Healthcare Conference
WAYNE, Pa., May 08, 2026 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammator...
Aclaris Therapeutics reports Q1 EPS (15c), consensus (16c)
Reports Q1 revenue $2M, consensus $1.32M. “Since the start of 2026, we have made great progress toward our goal of developing best-in-class compounds to address a variety of immuno-inflammatory diseas...
Aclaris Therapeutics reports Q1 EPS (15c), consensus (16c)
Reports Q1 revenue $2M, consensus $1.32M. “Since the start of 2026, we have made great progress toward our goal of developing best-in-class compounds to address a variety of immuno-inflammatory diseas...
Aclaris Therapeutics Earnings release: Q1 2026
Aclaris Therapeutics released its Q1 2026 earnings on May 7, 2026, summarizing the period's financial results.
Aclaris Therapeutics Quarterly report: Q1 2026
Aclaris Therapeutics has published its Q1 2026 quarterly earnings report on May 7, 2026.
Aclaris Therapeutics Slides: Corporate presentation
Aclaris Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on May 7, 2026.
Aclaris Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate and Clinical Update
- Full Top Line Results from Phase 1a SAD/MAD Trial of ATI-052 Exceed Aclaris' Target Profile, Validating Potential Best-in-Class Potency Advantage and Opportunity for Extended Dosing - - Unique Dual ...
Aclaris Therapeutics price target raised to $11 from $7 at Piper Sandler
Piper Sandler analyst Biren Amin raised the firm’s price target on Aclaris Therapeutics (ACRS) to $11 from $7 and keeps an Overweight rating on the shares following the company’s update…
Aclaris Therapeutics initiated with a Buy at Guggenheim
Guggenheim last night initiated coverage of Aclaris Therapeutics (ACRS) with a Buy rating and $12 price target The company has a promising interleukin-2-inducible T-cell kinase franchise strategy and ...
Aclaris Therapeutics initiated with a Buy at Guggenheim
Guggenheim analyst Seamus Fernandez initiated coverage of Aclaris Therapeutics (ACRS) with a Buy rating and $12 price target
Aclaris Therapeutics price target raised to $10 from $8 at Wedbush
Wedbush analyst Martin Fan raised the firm’s price target on Aclaris Therapeutics (ACRS) to $10 from $8 and keeps an Outperform rating on the shares. The firm notes the company…
Aclaris Therapeutics Transcript: Study update
Full top-line results from the ATI-052 phase I-A trial confirm strong PK, PD, and safety, supporting quarterly dosing and broad efficacy in TH2 diseases. ATI-2138 was selected for phase IIb development in lichen planus, targeting key inflammatory pathways in a high unmet need market.
Aclaris Therapeutics Press release: Study update
Aclaris Therapeutics issued a press release on April 28, 2026, disclosing material business information to investors.
Aclaris Therapeutics Slides: Study update
Aclaris Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on April 28, 2026.
Aclaris Therapeutics’ ATI-052 antibody shows PK efficacy in Phase 1a trial
Aclaris Therapeutics (ACRS) provided a clinical update on its biologic and oral inhibitor compounds including positive full top line results from the first-in-human Phase 1a single and multiple ascend...
Aclaris Therapeutics Announces Positive Full Top Line First-in-Human Results from Phase 1a Healthy Volunteer Clinical Trial of ATI-052, a Novel Potential First-in-Class Anti-TSLP/IL-4Rα Bispecific Antibody, and Announces Lichen Planus as Lead Indication for ATI-2138, an Oral ITK/JAK3 Inhibitor
- Positive Full Results from Phase 1a Trial of Anti-TSLP/IL-4Rα Bispecific Antibody ATI-052 Exceed Aclaris' Target Profile, Validating Potential Best-in-Class Potency Advantage and Opportunity for Ext...
Aclaris Therapeutics to Provide Clinical Update on Key Biologic and Oral Inhibitor Programs on April 28, 2026
WAYNE, Pa., April 27, 2026 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammat...
Aclaris Therapeutics management to meet virtually with Craig-Hallum
Virtual Meeting to be held on April 29 hosted by Craig-Hallum.
Aclaris Therapeutics Proxy statement: Proxy filing
Aclaris Therapeutics filed a proxy statement on April 23, 2026, providing details for shareholder voting and corporate governance matters.
Aclaris Therapeutics Proxy statement: Proxy filing
Aclaris Therapeutics filed a proxy statement on April 23, 2026, providing details for shareholder voting and corporate governance matters.
Aclaris Therapeutics initiated with an Outperform at Oppenheimer
Oppenheimer initiated coverage of Aclaris Therapeutics (ACRS) with an Outperform rating and $10 price target The firm sees a large commercial opportunity for the company’s immune-modulating portfolio ...
Aclaris Therapeutics Transcript: H.C. Wainwright 4th Annual Inflammatory Skin Disease Virtual Conference
ATI-052, a bispecific antibody for inflammatory skin diseases, shows best-in-class potency, long half-life, and potential for three-month dosing. Early data indicate strong efficacy and safety, with a robust pipeline including potent small molecules targeting diverse indications.
Aclaris Therapeutics to Participate in the H.C. Wainwright 4th Annual Inflammatory Skin Disease Virtual Conference
WAYNE, Pa., April 08, 2026 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammat...